Modern-day science has brought unique compounds, chemicals, and substances to humanity, each promising a range of health benefits. One such remarkable discovery is YCT529. This exceptional compound has shown much potential in enhancing overall health, including memory and cognitive ability. In this article, we will provide comprehensive information regarding YCT529.
What Is YCT529?
YCT529 is a small molecule that belongs to the fenamate chemical family, which is structurally similar to other fenamate-based molecules, such as mefenamic acid and flufenamic acid. Its development primarily focused on its therapeutic potential for treating neurological conditions, such as Alzheimer’s disease, Huntington’s disease, and epilepsy.
The chemical name of YCT529 is 2-(2-(4-bromophenyl) phenyl) propanoic acid.
The molecular formula of YCT529 is C15H13BrO2.
The formula weight of YCT529 is 319.17 g/mol.
YCT529's CAS number is 1052134-14-0.
Top Ten Keywords from Google and Synonyms
The Health Benefits of YCT529
Studies suggest that YCT529 may have several health benefits, especially in enhancing cognitive ability and reducing symptoms of neurological conditions. One of the primary mechanisms behind this is the drug's impact on brain inflammation. Chronic inflammation in the brain plays a significant role in the development of many neurological disorders.
YCT529 contains anti-inflammatory properties that inhibit the production of pro-inflammatory cytokines, effectively reducing inflammation in the brain. This helps protect the neurons and other crucial brain cells, enhancing overall brain function.
According to preclinical studies, YCT529 can offer the following potential effects to the body:
Cognitive enhancement: The drug may improve cognitive function by enabling better memory consolidation, learning, and information processing speed.
Neuroprotection: YCT529 contains neuroprotective properties that protect neurons and other vital brain cells from damage.
Alzheimer's treatment: Research using animal models suggests that YCT529 may be a promising therapeutic agent for Alzheimer's disease. The drug has demonstrated the ability to inhibit the formation of amyloid-beta peptides that play a crucial role in the disease's development.
YCT529 is a potent modulator of the brain's N-methyl-D-aspartate (NMDA) receptors, which regulate brain activity by modulating the neurotransmitter glutamate. These receptors play an essential role in neuronal communication, including the formation of new memories.
By regulating NMDA receptors, YCT529 reduces inflammation and protects the neurons, which can lead to better cognitive function.
Preclinical studies have shown that YCT529 is relatively safe for use, with no significant adverse effects reported. Moreover, the drug has not shown any signs of toxicity or damage to critical organs, such as the liver or kidneys.
While YCT529 has not demonstrated any significant adverse effects in preclinical studies, potential side effects such as headaches, dizziness, and gastrointestinal problems are possible. These side effects are similar to those associated with other non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen.